Clinical Trial Update: Understanding Mechanisms of Acquired Resistance to BIBW2992 [NA]

View source ↗

Summary

Completed clinical trial investigating mechanisms of acquired resistance to afatinib (BIBW2992) in EGFR-mutant non-small cell lung cancer. Results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-small Cell Lung Cancer, EGFR Mutations | NA | Status: COMPLETED | Results posted: 2018-03-09